In a report released today, Jessica Tassan from Piper Sandler reiterated a Buy rating on Health Catalyst (HCAT – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $8.47.
According to TipRanks, Tassan is a 3-star analyst with an average return of 1.7% and a 47.92% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Health Catalyst, CVS Health, and Evolent Health.
In addition to Piper Sandler, Health Catalyst also received a Buy from Canaccord Genuity’s Richard Close in a report issued today. However, on the same day, Stifel Nicolaus maintained a Hold rating on Health Catalyst (NASDAQ: HCAT).
See the top stocks recommended by analysts >>
HCAT market cap is currently $524.9M and has a P/E ratio of -3.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Health Catalyst (HCAT) Company Description:
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.
Read More on HCAT:
- Health Catalyst Executive Team Undergoes Major Reshuffle
- Health Catalyst Reports Fourth Quarter and Year End 2023 Results
- Health Catalyst’s Abe Health Registry receives QPP approval
- Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024
- Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls
